- Home
- UNP vs AMGN Comparison
UNP vs AMGN Comparison
Compare UNP & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNP
- AMGN
- Stock Information
- Founded
- UNP 1862
- AMGN 1980
- Country
- UNP United States
- AMGN United States
- Employees
- UNP N/A
- AMGN N/A
- Industry
- UNP Railroads
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UNP Industrials
- AMGN Health Care
- Exchange
- UNP Nasdaq
- AMGN Nasdaq
- Market Cap
- UNP 147.6B
- AMGN 152.1B
- IPO Year
- UNP N/A
- AMGN N/A
- Fundamental
- Price
- UNP $242.37
- AMGN $294.53
- Analyst Decision
- UNP Buy
- AMGN Buy
- Analyst Count
- UNP 20
- AMGN 22
- Target Price
- UNP $259.80
- AMGN $334.58
- AVG Volume (30 Days)
- UNP 2.6M
- AMGN 2.9M
- Earning Date
- UNP 10-24-2024
- AMGN 10-30-2024
- Dividend Yield
- UNP 2.21%
- AMGN 3.06%
- EPS Growth
- UNP 4.44
- AMGN N/A
- EPS
- UNP 10.88
- AMGN 7.83
- Revenue
- UNP $24,288,000,000.00
- AMGN $32,534,000,000.00
- Revenue This Year
- UNP $1.50
- AMGN $20.06
- Revenue Next Year
- UNP $3.79
- AMGN $3.50
- P/E Ratio
- UNP $22.28
- AMGN $37.60
- Revenue Growth
- UNP 0.61
- AMGN 21.25
- 52 Week Low
- UNP $218.55
- AMGN $260.68
- 52 Week High
- UNP $258.66
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- UNP 56.09
- AMGN 40.27
- Support Level
- UNP $231.84
- AMGN $275.56
- Resistance Level
- UNP $241.09
- AMGN $328.25
- Average True Range (ATR)
- UNP 4.38
- AMGN 8.54
- MACD
- UNP 0.47
- AMGN -1.82
- Stochastic Oscillator
- UNP 57.92
- AMGN 36.00
About UNP Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the us, UP generated $24 billion of revenue in 2023 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, fertilizers, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and historically derives roughly 10% of its revenue hauling freight to and from Mexico.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.